Lyophilized from sterile PBS, pH 7.4. Normally 5 % - 8% trehalose is added as protectants before lyophilization. Please see Certificate of Analysis for specific instructions of reconstitution.
Target:
CB1
Elisa plates were pre-coated with 0.5 µg/per well purified human CB1 full length membrane nanoparticles. Serial diluted anti-CB1 monoclonal antibody (orb1174025) solutions were added, washed, and incubated with secondary antibody before Elisa reading. From above data, the EC50 for anti-CB1 monoclonal antibody binding with CB1 full length membrane nanoparticles is 439.6 ng/ml.
FACS analysis of CB1 MNPs A. Negative Control 1: CB1 full length membrane nanoparticles samples were stained only with Goat anti-human lgG 488 secondary antibody. B. Negative Control 2: Control membrane nanoparticles samples were stained with anti-CB1 antibody at 2 µg/mL, followed by Goat anti-human IgG 488 secondary antibody. C. Negative Control 3: CB1 full length membrane nanoparticles samples were stained with anti-CCR8 antibody (an irrelevant antibody) at 2 µg/mL, followed by Goat anti-human IgG 488 secondary antibody. D. CB1 full length membrane nanoparticles samples were stained with anti-CB1 antibody at 2 µg/mL, followed by Goat anti-human IgG 488 secondary antibody.
* VAT and and shipping costs not included. Errors and price changes excepted
